Bulk Pharmaceutical API Sources for ALUNBRIG

Bulk Pharmaceutical API Sources for ALUNBRIG

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-12857
AbaChemScene		CS-4278
ChemShuttle		140455
AbovChem LLC		HY-12857
AKos Consulting & Solutions		AKOS030257612
Activate Scientific		AS59455
abcr GmbH		AB479723

Bulk Active Pharmaceutical Ingredient (API) Sources for ALUNBRIG (brigatinib)

Last updated: July 28, 2025

Introduction

ALUNBRIG (brigatinib) is an advanced targeted therapy indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). As a second-generation ALK inhibitor, brigatinib offers improved efficacy and management of resistance compared to first-generation drugs like crizotinib. Ensuring a reliable supply of high-quality API is crucial to maintaining the drug’s commercial continuity, regulatory compliance, and market competitiveness. This article provides a comprehensive analysis of the global bulk API sources for brigatinib, examining key manufacturers, geopolitical considerations, quality standards, and supply chain reliability.

Overview of ALUNBRIG (brigatinib)

Developed by Ariad Pharmaceuticals and later acquired by Takeda Pharmaceutical Company, ALUNBRIG is a potent and selective ALK inhibitor used in treating ALK-positive NSCLC. The manufacturing process of brigatinib involves complex organic synthesis, demanding strict regulatory adherence to Good Manufacturing Practices (GMP). The API sourcing landscape must therefore satisfy quality, quantity, and legal regulatory frameworks established by agencies such as the FDA, EMA, and other health authorities.

Global API Manufacturing Landscape for Brigatinib

Major API Producers and Their Capabilities

1. Takeda Pharmaceutical Company

As the originator of ALUNBRIG, Takeda maintains internal API manufacturing capabilities to guarantee supply chain security for brigatinib. The company's vertically integrated approach encompasses GMP-compliant production at several facilities worldwide, primarily in Japan and the United States. Takeda’s in-house API manufacturing ensures consistent quality control, regulatory compliance, and rapid response to demand fluctuations.

2. Contract Manufacturing Organizations (CMOs)

Given the intricate synthesis of brigatinib, several CMOs have established production capacity, including:

• Boehringer Ingelheim – Known for expertise in complex APIs, Boehringer Ingelheim offers high-volume API manufacturing with rigorous quality standards, serving as a reliable partner for pharmaceutical companies requiring bulk API supply.

• Samsung Biologics – Although primarily focused on biologics, Samsung’s expanding chemical manufacturing division claims capabilities in small-molecule APIs, including potentially brigatinib, supported by their large-scale GMP facilities in South Korea.

• WuXi AppTec – A globally recognized CMO with extensive experience in small-molecule API synthesis, WuXi offers custom synthesis and scale-up services, including complex kinase inhibitors like brigatinib.

• Korea Pharmaceutical and Bio-Pharma (KPB) – With dedicated chemical manufacturing capacities, KPB has invested in advanced synthetic chemistries aligned with ALUNBRIG’s production requirements.

3. Other Noteworthy API Suppliers

• Laurus Labs (India): Laurus Labs has developed expertise in small-molecule API synthesis, including kinase inhibitors, with GMP-certified manufacturing capacities. Its strategic emphasis on APIs for targeted cancer therapies positions it as a potential supplier of brigatinib API.

• Hikal Ltd. (India): Known for complex molecule API manufacturing, Hikal offers flexibility and scale, aligning with multinational pharmaceutical demands.

• SIGNATURE CHEMICALS – A smaller but growing API manufacturer with capabilities in multi-step syntheses for kinase inhibitors.

Quality and Regulatory Considerations

API suppliers must adhere to GMP compliance, displaying certifications such as FDA Establishment Inspection Reports (EIR), European EMA GMP certification, and other relevant compliance standards. For brigatinib, due to its status as an injectable or oral medication, strict impurity profile management, stability, and bioequivalence data are mandatory. The suppliers listed above have demonstrated such compliance in their approvals.

Geographical Distribution and Its Impact on Supply Chain

API manufacturers are predominantly based in India, China, South Korea, Japan, and the United States. These regions offer varying advantages:

• India & China: Cost advantages, large-scale manufacturing, and expanding GMP facilities. However, geopolitical considerations and regulatory scrutiny historically pose supply chain risks.
• South Korea & Japan: Advanced manufacturing standards, strict regulatory compliance, and high-quality assurance specific to regulatory markets like the US and EU.
• United States & Europe: Smaller but high-quality API producers, often focused on niche, high-value APIs with stringent regulatory oversight.

Supply Chain Challenges

Potential bottlenecks include:

• Regulatory disruptions — Due to global trade tensions or policy shifts impacting manufacturing export permissions.
• Capacity constraints — Limited number of suppliers with requisite complex synthesis capabilities.
• Quality assurance — Variability among suppliers, requiring rigorous audits and supply chain validation.
• Raw material sourcing — Dependence on specialized chemical intermediates subject to geopolitical and environmental factors.

Emerging Trends and Future Prospects

• Increased reliance on CMOs — Driven by patent expiration and cost efficiencies.
• Geographic diversification — To mitigate risks associated with concentrated supply chains.
• Advanced synthetic methodologies — Such as continuous flow chemistry, potentially reducing production time and costs.
• Regulatory harmonization — Facilitating smoother approval processes for new API sources.

Conclusion

The supply of brigatinib API is concentrated among Takeda’s internal facilities and a select group of reputable CMOs with proven GMP compliance. The Indian and South Korean markets feature prominent API manufacturers suited for large-scale production, whereas North American and European entities focus on high-quality assurance. The complex synthesis of brigatinib necessitates a carefully managed supplier network to ensure supply continuity, quality, and regulatory compliance. Diversifying suppliers and investing in supply chain resilience are critical strategies for stakeholders.

---

Key Takeaways

• Strategic Supplier Selection: Takeda’s internal API production forms the cornerstone of supply, supplemented by a trusted network of CMOs with GMP-certified facilities.
• Regulatory Vigilance: Suppliers must meet stringent GMP standards, with ongoing audits to maintain compliance.
• Geographical Diversification: Relying solely on one region exposes vulnerabilities; a diversified sourcing strategy mitigates geopolitical and logistical risks.
• Emerging Manufacturing Technologies: Investment in innovative synthesis methods and flexible manufacturing can reduce costs and enhance responsiveness.
• Supply Chain Resilience: Maintaining multiple qualified suppliers and monitoring geopolitical developments ensures consistent API availability.

---

FAQs

1. Who are the primary API manufacturers for brigatinib globally?
Takeda Pharma, along with CMOs such as WuXi AppTec, Samsung Biologics, Laurus Labs, and Hikal Ltd., serve as primary sources for brigatinib API.

2. What regulatory standards do API suppliers for brigatinib need to meet?
Suppliers must comply with GMP standards established by authorities such as the FDA, EMA, and other regional regulators, ensuring high purity, stability, and consistent quality.

3. How does geopolitical risk impact brigatinib API supply?
Suppliers concentrated in specific regions like India and China face risks related to trade policies, export restrictions, or political instability, emphasizing the importance of geographical diversification.

4. Are there upcoming alternative sources of brigatinib API?
Yes, growing capacities in South Korea and India, along with advancements in synthetic chemistry, may lead to new suppliers or expanded existing capacities, reducing supply reliance on a handful of producers.

5. What role do CMOs play in the future of brigatinib API sourcing?
CMOs facilitate scalable, flexible, and cost-effective API production while enabling Takeda and other pharmaceutical companies to adapt to market demands and maintain drug supply continuity.

---

Sources:
[1] Takeda Pharmaceutical Company. (2022). ALUNBRIG (brigatinib) prescribing information.
[2] WuXi AppTec. (2023). API manufacturing capabilities.
[3] KFDA & EMA certifications. (2022). Regulatory compliance reports for API manufacturers.
[4] Industry reports on API manufacturing and supply chain analysis, IQVIA and Evaluate Pharma.